Figure 7.

The value of CMLS in predicting immunotherapy response in MUC patients

(A) The restricted mean survival (RMS) time difference by 6 months and 1 year after treatment between high- and low-CMLS groups. (B) The long-term survival (LTS) difference after 3 months of treatment between high- and low-CMLS groups. (C) The distribution of CMLS in different immunotherapy response groups. (D) Differences in the degree of activation between high- and low-CMLS groups at each step of TIP. (E) The TIDE algorithm predicts response to immunotherapy between high- and low-CMLS groups. (F) The subclass mapping algorithm predicts response to immunotherapy between high- and low-CMLS groups. (G) Survival analysis of high- and low-CMLS groups in GSE78220. (H) Survival analysis of high- and low-CMLS group in GSE135222. (I) Distribution of CMLS in different immunotherapy response groups of GSE91061.